A wire-watching FBvian pointed me in the direction of this story, which says that Pfizer, the maker of the smoking cessation drug Chantix, will be adding additional (and more prominent) warning labels to the drug, based on patient reports of depression and suicidal thoughts. As you may remember, and the CNN Money piece points out, the drug came under scrutiny last September following the death of Carter Albrecht.
Get the D Brief Newsletter
Dallas’ most important news stories of the week, delivered to your inbox each Sunday.